Telaprevir Trial Boasts 80% Hepatitis C Cure Rate | Hepatitis Central

The latest research & treatment news about Hepatitis C infection, diagnosis, symptoms and treatment.

Menu Search
Previous

Hepatitis C: Curable or Incurable Disease?

Back to News Homepage
Next

Hep C Study Finds Big Gender Inequality in Liver Transplant Risks

Telaprevir Trial Boasts 80% Hepatitis C Cure Rate

The Editors at Hepatitis Central
November 4, 2009

Print this page

Recent data from a Phase II trial claims that twice daily dosing of telaprevir cured Hepatitis C in over 80 participants.

Vertex Hep C Drug Cures 80% at New Dose: Study

10/31/09

By Adam Feuerstein

BOSTON (TheStreet) — More than 80% of hepatitis C patients were cured after treatment with a new twice-daily dose of the experimental drug telaprevir made by Vertex Pharmaceuticals(VRTX Quote), according to data from a phase II study released Saturday.

Data from the new study demonstrates that a more convenient twice-daily dose of telaprevir is just as effective and safe as the thrice-daily dose, Vertex said.

Read the entire article:
http://www.thestreet.com/story/10619851/1/vertex-hep-c-drug-cures-80-at-new-dose-study.html?cm_ven=GOOGLEN

No Comments - be the first!
Share
Share
Previous

Hepatitis C: Curable or Incurable Disease?

Back to News Homepage
Next

Hep C Study Finds Big Gender Inequality in Liver Transplant Risks

Requirements for using and reposting articles

Comments

HepatitisCentral.com provides information regarding hepatitis and liver disease. Comments are available to the community in order to discuss these topics and obtain answers to questions through community members. The Editors at HepatitisCentral.com will not be responding to questions or comments posed in article comments.